|
FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
|
01 May 2020 |
|
FDA reiterates importance of close patient supervision for 'off-label' use of antimalarial drugs
|
24 April 2020 |
|
FDA encourages recovered patients to donate plasma for development of blood-related therapies
|
16 April 2020 |
|
FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19
|
03 April 2020 |
|
FDA Continues to Accelerate Development of Novel Therapies for COVID-19
|
01 April 2020 |
|
The FDA is facilitating access to convalescent plasma collected from recovered COVID-19 patients
|
25 March 2020 |
|
FDA continues to facilitate development of COVID-19 treatments
|
20 March 2020 |
|
FDA and FTC warn seven companies selling fraudulent products that claim to treat or prevent COVID-19
|
09 March 2020 |
|
FDA approves new treatment for adults with Cushing's disease
|
06 March 2020 |
|
FDA approves first generic of Daraprim
|
28 February 2020 |
|
FDA takes action with Indian Government to protect consumers from illicit medical products
|
18 February 2020 |
|
FDA approves first drug for treatment of peanut allergy for children
|
31 January 2020 |
|
FDA continues strong support of innovation in development of gene therapy products
|
29 January 2020 |
|
FDA approves first treatment option specifically for patients with epithelioid sarcoma
|
24 January 2020 |
|
FDA approves first treatment for thyroid eye disease
|
21 January 2020 |
|
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
|
10 January 2020 |
|
FDA approves new treatment for adults with migraine
|
01 January 2020 |
|
FDA approves first generics of Eliquis
|
26 December 2019 |
|
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
|
20 December 2019 |
|
FDA approves new type of therapy to treat advanced urothelial cancer
|
19 December 2019 |